by gnsadmin | Mar 16, 2021 | Press Releases
Somerville, MA: GNS Healthcare, an AI company creating in silico patients to simulate disease progression and drug treatment at the individual patient level, is pleased to announce that accomplished finance executive Alan Kilyk has joined the company’s leadership team...
by Kayla Mossien | Jan 18, 2021 | Press Releases
Partnership enables enhanced capability to discover new targets and prognostic markers Somerville, MA: GNS Healthcare, the leading AI-driven precision medicine company, today announced a partnership with QIAGEN, the leading global provider of Sample to Insight...
by Simona Gilman | Jul 21, 2020 | Press Releases
AI-driven in silico patients used to accurately identify types of immune responses in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC). CAMBRIDGE, Mass.– [July 21, 2020] – GNS Healthcare (GNS), a leading AI and simulation company,...
by Simona Gilman | Jun 25, 2020 | Featured Posts, Press Releases
A transformative innovation GeminiTM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma GNS Healthcare, an AI-driven precision medicine company, today announced the launch of...
by Simona Gilman | Jun 18, 2020 | Press Releases
Partnership Aims to Answer Key Questions in Multiple Myeloma Patient Care and Accelerate Discovery and Development of New Treatments Cambridge, MA – June 18, 2020– GNS Healthcare and the Multiple Myeloma Research Foundation (MMRF) today announced a five-year...
by Simona Gilman | May 28, 2020 | Press Releases
Study results are from the DREAM Challenge and are published in Leukemia CAMBRIDGE, Mass.– May 28, 2020 – GNS Healthcare (GNS), a leading AI-driven precision medicine, announced results of a recently published collaboration that uncovered transcription factor PHF19 as...
